The United States Food and Drug Administration (USFDA) has successfully completed Pre-Approval Inspection (PAI) and GMP audit at Granules India’s Unit IV facility located at Visakhapatnam, Andhra Pradesh, India, with zero 483 observations. The inspection conducted from June 26, 2023 to June 30, 2023. Unit IV facility located at Visakhapatnam manufactures Active Pharmaceutical Ingredients (API).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
